Co-Authors
This is a "connection" page, showing publications co-authored by DIANE C BODURKA and ROBERT COLEMAN.
Connection Strength
1.104
-
Transfusion use and effect on progression-free, overall survival, and quality of life in upfront treatment of advanced epithelial ovarian cancer: evaluation of the European Organization for Research and Treatment EORTC-55971 Cohort. Int J Gynecol Cancer. 2023 01 03; 33(1):1-9.
Score: 0.229
-
Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study. Gynecol Oncol. 2021 04; 161(1):104-112.
Score: 0.200
-
Phase Ib/II study of weekly topotecan and daily gefitinib in patients with platinum resistant ovarian, peritoneal, or fallopian tube cancer. Int J Gynecol Cancer. 2020 11; 30(11):1768-1774.
Score: 0.196
-
Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study. Cancer. 2012 Jun 15; 118(12):3087-94.
Score: 0.106
-
Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol. 2006 Aug; 108(2):361-8.
Score: 0.073
-
Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol Oncol. 2006 Apr; 101(1):126-31.
Score: 0.070
-
Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. Am J Obstet Gynecol. 2021 02; 224(2):191.e1-191.e15.
Score: 0.048
-
Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum. J Clin Oncol. 2017 Apr 01; 35(10):1103-1111.
Score: 0.038
-
A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies. Clin Cancer Res. 2011 Nov 01; 17(21):6840-6.
Score: 0.026
-
Phase I clinical trials in 85 patients with gynecologic cancer: the M. D. Anderson Cancer Center experience. Gynecol Oncol. 2010 Jun; 117(3):467-72.
Score: 0.024
-
Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol. 2009 Jul; 114(1):48-52.
Score: 0.022
-
Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. Clin Cancer Res. 2008 Sep 01; 14(17):5437-46.
Score: 0.021
-
Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol. 2008 Mar; 108(3):510-4.
Score: 0.020
-
Lymphatic mapping and sentinel node biopsy in women with high-risk endometrial cancer. Gynecol Oncol. 2007 Jan; 104(1):100-3.
Score: 0.018
-
Intraoperative lymphatic mapping and sentinel node identification with blue dye in patients with vulvar cancer. Gynecol Oncol. 2001 Nov; 83(2):276-81.
Score: 0.013